Gene Editing is the ability to make highly specific changes in the DNA sequence of a living organism, essentially customizing its genetic makeup. It demonstrates great potential in gene research, gene therapy and genetic improvement. The Gene Editing concept includes major US-listed companies whose businesses are involved in gene editing.
- 1437.915
- +8.001+0.56%
Wednesday Ends With Index Decline | Wall Street Today
FDA Investigating Safety Risks of Bluebird's Skysona
FDA Investigating Serious Risk Of Hematologic Malignancy Following Skysona (Elivaldogene Autotemcel)
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Expert Outlook: Agilent Technologies Through The Eyes Of 4 Analysts
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Caribou Biosciences Analyst Ratings
Dow Falls After Record, Trump Talks Tariffs on Day One | Live Stock
Agilent Technologies Analyst Ratings
Agilent Technologies, Inc. (A) Q4 2024 Earnings Call Transcript Summary
Agilent Technologies Sees Q1 Adj. EPS $1.25-$1.28 Vs $1.37 Est.; Revenue $1.65B-$1.68B Vs $1.697B Est.
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Agilent Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
S&P 500, Dow Hit Records Right After Open | Live Stock